

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sisram Medical Ltd
復銳醫療科技有限公司*
(Incorporated in Israel with limited liability)
(Stock Code: 1696)

VOLUNTARY ANNOUNCEMENT
TIANJIN XINGSIYI INVESTMENT

The board of directors of Sisram Medical Ltd (the “**Company**”) is pleased to announce that, on 10 January 2022, the Company entered into an investment agreement (the “**Investment Agreement**”) with, among others, (i) Suzhou Fujian Xingyi Venture Investment Partnership (Limited Partnership)* (蘇州復健星熠創業投資合夥企業(有限合夥)) (“**Fosun Health Fund (Suzhou)**”), (ii) Tianjin Fosun Haihe Healthcare Industry Fund Partnership (Limited Partnership)* (天津復星海河醫療健康產業基金合夥企業(有限合夥)) (“**Fosun Health Fund (Tianjin)**”) and (iii) Tianjin Xingsiyi Bio-technology Company Limited* (天津星絲奕生物科技有限公司) (the “**Target**”) in relation to the setting up of the Target with an aggregate investment amount of RMB25 million into the Target, of which, the Company agreed to contribute RMB2.6 million in total and the registered capital of the Target is RMB2.5 million. Immediately upon the completion of the investment by the Company pursuant to the Investment Agreement, the Company will hold approximately 10.40% of the total issued shares of the Target.

As at the date of this announcement, the Target is to be set up for engaging in the research and development, technical services and supply of silk fibroin-sodium hyaluronate composite gel-and facial implant thread- products. The Company believes that the proposed investment under the Investment Agreement would enable the Company to enhance the Group’s medical aesthetic knowhow and to explore cross-selling opportunities. [*Company to confirm*]

Each of Fosun Health Fund (Suzhou) and Fosun Health Fund (Tianjin) is a limited liability partnership incorporated in the PRC whose respective general partner is a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥(集團)股份有限公司), a controlling shareholder of the Company. The transaction contemplated under the Investment Agreement constituted a fully exempted connected transaction of the Company pursuant to Rule 14A.76 of the Hong Kong Listing Rules.

On behalf of the Board
Sisram Medical Ltd
復銳醫療科技有限公司*
Yi LIU
Chairman

Hong Kong, 10 January 2022

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yi LIU, Mr. Lior Moshe DAYAN and Mr. Guojun BU as Executive Directors; Mr. Yifang WU, Mr. Yao WANG and Ms. Rongli FENG as Non-Executive Directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as Independent Non-executive Directors.

* for identification purpose only